ProQR Therapeutics develops novel therapeutic medicines, focusing on products like AX-0810 for cholestatic diseases and AX-1412 for cardiovascular diseases. Other pipeline programs target Rett syndrome, NASH, obesity/Type 2 diabetes, and rare metabolic conditions. The company also develops the Axiomer RNA base-editing platform technology. ProQR has license agreements with several institutions and a collaboration with Eli Lilly for genetic disorder treatments.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 4.4 |